- Dr. Swanson most recently co-founder of publicly listed PolarityTE, a biotech company focused around developing regenerative tissue products, biomaterials
- Prior to PolarityTE, Dr. Swanson served as resident in plastic and reconstructive surgery at John Hopkins University School of Medicine
- Healthtech Solutions has adopted a unique portfolio business model, recently announcing acquisition of precision oncology company Varian Biopharmaceuticals
Healthtech Solutions (OTC: HLTT), the parent company of Varian Biopharmaceuticals Inc., Medi-Scan Inc. and RevHeart Inc., have recently announced the appointment of Edward Swanson, MD as the company’s new Chief Executive Officer (https://ibn.fm/444X7). The appointment, which is effective as of May 14, 2021, will see Dr. Swanson replace David Rubin as Healthtech Solutions’ CEO.
“With Ned Swanson at the helm of Healthtech Solutions, we have the leadership and expertise of an individual who has demonstrated success at both medical bioengineering and effective public company stewardship at C-level,” said Healthtech Solutions Chairman David Rubin. “His direction will facilitate a rise to a new level for the company and serve to deliver continued growth and shareholder value.”
Dr. Swanson has a long and distinguished background that makes him particularly well suited to lead Healthtech going forward, drawing from a broad array of scientific, clinical and industry specific experiences. Dr. Swanson is a co-founder of PolarityTE, Inc. (NASDAQ: PTE), a biotech company focused around developing a range of regenerative tissue products and biomaterials, led by its flagship product SkinTE(R).
During his tenure at PolarityTE, Dr. Swanson was able to draw on a range of experiences in building and leading a publicly listed company, serving in a wide variety of roles, including director, chief operating officer, and chief medical officer. In addition to his positions at PolarityTE, Dr. Swanson also served as the CEO of PolarityTE’s subsidiaries, Utah CRO Services Inc. and IBEX Preclinical Research Inc., which specialized in offering preclinical contract research services.
Prior to PolarityTE, Dr. Swanson was a resident in plastic and reconstructive surgery at The John Hopkins University School of Medicine. During his tenure at John Hopkins, Dr. Swanson published over 45 peer-reviewed papers, authored four book chapters, and delivered upwards of 30 conference presentations. Dr. Swanson is a graduate of the University of Pennsylvania’s School of Engineering and Applied Science and obtained his M.D. from Harvard Medical School.
Healthtech Solutions has sought to adopt a unique, portfolio-style business model, with the company recently agreeing to purchase Varian Biopharmaceuticals Inc., a precision oncology company developing novel therapeutics for the treatment of cancer (https://ibn.fm/XP0L7). The acquisition will add to HLTT’s growing healthcare portfolio, which also features cloud-based ultrasound technology provider, Medi-Scan Inc., as well as RevHeart Inc., a wholly owned subsidiary focused around treating COVID-related heart muscle injury.
“I am thrilled to be joining the Healthtech team to build out a unique portfolio-style business model to bring innovative biotech and medical device technologies to the market and impact patient lives,” said Dr. Swanson. “The decentralized development of assets in this structure leverages nimble operating efficiencies at the subsidiary level combined with the experience and skillsets of the management team of Healthtech.”
For more information on, visit the company’s website at www.HealthTechSolutions.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.